[ad_1]
Hey! It’s Madison in New York. Novo Nordisk’s weight loss drug Wegovy cut heart attacks by 20% in a study — does that make it a heart drug? Before we get into it…
Last week, a much-anticipated study from Novo Nordisk showed that people with obesity and a history of heart issues were 20% less likely to suffer a cardiovascular event when taking Wegovy. Wall Street hailed the results as a slam dunk, which helped boost Novo and fellow drugmaker Eli Lilly’s shares to record highs. Wegovy, suddenly, appeared to be not only a weight-loss wonder but also a heart-attack preventer.
[ad_2]
Source link
